Heidrun Grosch

A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation–Positive NSCLC Patients

Giorgio V. Scagliotti, Denis Moro‐Sibilot, Jens Kollmeier et al. · Journal of Thoracic Oncology · 2019 · 74 citations

Medicine, Randomized-controlled Phase 2, Immunology +8

A randomized, open-label, phase 2 study of emibetuzumab plus erlotinib (LY+E) and emibetuzumab monotherapy (LY) in patients with acquired resistance to erlotinib and MET diagnostic positive (MET Dx+) metastatic NSCLC.

D. Ross Camidge, Teresa Morán, Ingel Demedts et al. · Journal of Clinical Oncology · 2016 · 31 citations

Independent Hgf/met Signaling, Immunology, Metastatic Nsclc +16

Dosimetric comparison of advanced radiotherapy approaches using photon techniques and particle therapy in the postoperative management of thymoma

Matthias F. Haefner, Vivek Verma, Nina Bougatf et al. · Acta Oncologica · 2018 · 29 citations · Full text

A Randomized, Open-Label Phase II Study Evaluating Emibetuzumab Plus Erlotinib and Emibetuzumab Monotherapy in MET Immunohistochemistry Positive NSCLC Patients with Acquired Resistance to Erlotinib

D. Ross Camidge, Teresa Morán, Ingel Demedts et al. · Clinical Lung Cancer · 2022 · 27 citations · Full text

Emibetuzumab Monotherapy, Acquired Resistance, Medicine +10

Early Development of Ubiquitous Acanthocytosis and Extravascular Hemolysis in Lung Cancer Patients Receiving Alectinib

J. Kunz, Christiane Wiedemann, Heidrun Grosch et al. · Cancers · 2022 · 14 citations · Full text

Early Development, Immunology, Pathology +19